TAKTIKAL
12.1.2022 23:21:11 CET | Business Wire | Press release
Taktikal (www.taktikal.io ), a developer of next generation digital trust solutions, announced that Brunnur Ventures had invested $2 million into the company to drive customer acquisition and the international build out of its business strategy. Taktikal provides enterprise-grade electronic signatures solutions to meet the growing need for companies to automate and streamline processes that require identification, authentication, and authorisation. Taktikal leverages deep expertise with the state-level authentication infrastructure of Nordic nation states such as Iceland to offer faster processing, greater efficiency in document management, reduced operational risk and a better customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112006022/en/
New funding will accelerate international sales expansion of the Company’s e-signature software suite into the global SME market, where ad hoc, low security, home-baked processes are pervasive today.
“We’re delighted to announce the close of our first institutional investment round, with participation by Brunnur Ventures, whom we welcome as experienced and valued shareholders in the Company for the next phase of our development,” says Taktikal’s CEO Valur Gunnarsson, “People are commonly emailing sensitive documents such as passport and driver’s license scans in a highly insecure way. Taktikal brings out-of-the-box enterprise-grade document signing and other processes to a vast potential customer base of corporates needing to provide best-in-class workforce and customer onboarding experiences, and driven by increasing security, as well as AML, KYC, PEP and sanctions requirements.”
“To be successful, businesses must find ways to streamline operations and reduce administrative bottlenecks. Taktikal offers an outstanding service to meet these needs,” commented Kjartan Olafsson, Investment Manager at Brunnur Ventures who will take a seat in Taktikal’s board, “We believe that a transformation is overdue in this space akin to the revolution we’ve seen in many other workflow areas such as CRM and project management.”
ABOUT TAKTIKAL
Taktikal ehf, based in Iceland is a leading vendor of next generation enterprise grade electronic signature solutions, covering application-level integrated smart forms, in-browser fill-and-sign, and email. The Company serves a growing need for secure, best-in-class process to support corporate requirements for automated customer and workforce onboarding, KYC and AML processes and in-application electronic identity.
For more information please visit: www.taktikal.io
ABOUT BRUNNUR VENTURES
Brunnur Ventures is venture capital firm based in Iceland focused on seed and early-stage investments, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent.
Brunnur Ventures currently manages two funds, Brunnur I and Brunnur II, with fund operation and administration provided by Landsbref, a fund management company licensed by the Icelandic Financial Supervisory Authority.
For more information please visit:www.brunnurventures.com
Forward-Looking Statements
This press release may contain certain forward-looking statements concerning the financial condition, results of operations and businesses of the Company. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this presentation. The information in this presentation is subject to updating, completion, revision, further verification, and amendment without notice and the Company does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112006022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release
Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
